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The bHLH transcription factors that regulate early
development of the central nervous system can
generally be classified as either antineural or proneu-
ral. Initial expression of antineural factors prevents
cell cycle exit and thereby expands the pool of neural
progenitors. Subsequent (and typically transient)
expression of proneural factors promotes cell cycle
exit, subtype specification, and differentiation.
Against this backdrop, the bHLH transcription factor
Olig2 in the oligodendrocyte lineage is unorthodox,
showing antineural functions in multipotent CNS
progenitor cells but also sustained expression and
proneural functions in the formation of oligodendro-
cytes. We show here that the proliferative function
of Olig2 is controlled by developmentally regulated
phosphorylation of a conserved triple serine motif
within the amino-terminal domain. In the phosphory-
lated state, Olig2 maintains antineural (i.e., promi-
totic) functions that are reflected in human glioma
cells and in a genetically defined murine model of
primary glioma.
INTRODUCTION
During central nervous system (CNS) development, regulation of
pool size for diversified neuronal and glial progenitor populations
involves complex interactions of spatially restricted organizing
signals, mitogens, and other developmental cues that promote
differentiation through intracellular signaling and activation of
a variety of transcription factors (Edlund and Jessell, 1999).
Proneural bHLH transcription factors (e.g., Ascl1) and antineuro-
genic bHLH and HLH transcription factors from the Hes, Hey,
and Id families play pivotal roles in specification and differentia-
tion of neurons and glia. At early times in development, anti-
neurogenic factors prevail over their proneurogenic counterparts
so as to sustain replication competence and expand the pool of
neural progenitors. At later times, proneurogenic factors become906 Neuron 69, 906–917, March 10, 2011 ª2011 Elsevier Inc.dominant as to promote cell cycle exit, neuronal differentiation,
and subtype specification (Jessell, 2000; Ross et al., 2003;
Rowitch, 2004).
Oppositional functions of antineurogenic and proneurogenic
transcription factors can be regulated at the level of gene
expression or protein activity. In the developing telencephalon,
for example, Delta/Notch signaling stimulates expression of
antineural Hes transcription factors (reviewed in Justice and
Jan, 2002), which in turn directly suppress expression of neural
factor Ascl1. Conversely, suppression of Notch/Delta signaling
(through relief of lateral inhibition) is needed for expression and
function of proneural factors (reviewed in Beatus and Lendahl,
1998). According to the prevailing view of neurogenesis, the tran-
sient expression of proneural bHLH transcription factors such as
Mash1, Ngn1, or Ngn2 induces a second sustained wave (or
waves) of bHLH neuronal differentiation transcription factors
(e.g., NeuroD, NeuroD2), which then promote terminal differenti-
ation. Notably, neither proneural nor antineural bHLH transcrip-
tion factors are generally expressed in fully formed, terminally
differentiated neurons (Kageyama and Nakanishi, 1997; Lee,
1997). The proneural factor Ascl1 also plays a role in specifica-
tion of oligodendrocytes (Parras et al., 2004). Even in this
gliogenic context, however, Ascl1 expression is confined to
immature precursors and is not seen in differentiated
oligodendrocytes.
One neurogenic factor that defies this simple binary functional
characterization is Olig2—a bHLH transcription factor that
shows both antineural functions and proneural functions at
different stages in the formation of the oligodendrocyte lineage.
In the embryonic spinal cord, for example, Olig2 is expressed
initially in the pMN domain, where it functions at early times in
pattern formation (Lu et al., 2002) and as an antineural factor to
sustain the replication competent state of those pMN progeni-
tors that are destined for second wave gliogenesis (Lee et al.,
2005) (see Discussion). Olig2 is likewise expressed inmultipotent
neurospheres derived from the embryonic forebrain, where it is
required for optimum proliferation in vitro (Ligon et al., 2007).
As development proceeds, Olig2 acquires a proneural function
to specify formation of oligodendrocyte progenitors. However,
unlike other proneural factors with roles in gliogenesis such as
Ascl1 that are not expressed in their terminally differentiated
end products (Parras et al., 2004), Olig2 expression is sustained
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(Lu et al., 2000), where it appears to have ongoing biological
functions (Cai et al., 2007). A similar antineural/proneural
dichotomy is observed in the postnatal brain, where Olig2 is
expressed in rapidly cycling transit-amplifying cells (‘‘Type C’’
cells) of the subventricular zone as well as in terminally differen-
tiated myelinating oligodendrocytes that arise from these cells
(Jackson et al., 2006; Menn et al., 2006).
Intuitively, it would seem that Olig2 cannot be doing the same
thing in replication-competent progenitor cells and in terminally
differentiated oligodendrocytes. The regulatory functions of
Olig2 in proliferation of neural progenitors are of special interest
due to provocative links to the literature on human gliomas.
Tissue microarray and in situ hybridization studies show that
Olig2 is expressed in 100% of the human diffuse gliomas,
regardless of grade. Beyond merely marking the glioma cells,
Olig2 expression is actually required for intracranial tumor forma-
tion in a murine model of glioma that recapitulates the genetics
and histology of high-grade glioma in humans. The tumorigenic
‘‘gatekeeper’’ function of Olig2 reflects, at least in part, the fact
that the gene encoding p21WAF1/CIP1, a tumor suppressor and
inhibitor of stem cell proliferation (hereafter referred to as
‘‘p21’’), is directly repressed by Olig2 in murine neural progeni-
tors and human gliomas (Ligon et al., 2007).
How might the distinct functions of Olig2 be dynamically
modulated to suit biological context? Using mass spectroscopy,
phosphorylation state-specific antibodies, and site-directed
mutagenesis, we show here that the separate functions of
Olig2 in progenitor self-renewal and oligodendrocyte develop-
ment are controlled in part by developmentally regulated
phosphorylation of a conserved triple serine motif within the
amino-terminal domain. The promitotic functions of this triple
serine motif are reflected in human glioma neurosphere cultures
and in a murine model of primary glioma (the most common
manifestation of the disease in humans) (Kleihues and Cavenee,
2007).
RESULTS
Identification of a Triple Phosphoserine Motif in Olig2
Using immunoaffinity chromatography, we purified microgram
quantities of endogenous Olig2 protein from both normal murine
neurosphere cultures and from gliomas generated by orthotopic
transplant of primary human tumor neurospheres (see Figure S1
available online). High-confidence phosphorylation sites within
Olig2 were mapped by mass spectroscopy (Figures 1, S1D,
and S2). As indicated in Figure S1, a number of potential
phosphorylation sites within Olig2 can be detected by computer
algorithm. However, mass spectroscopy reveals that very few of
these potential sites are actually utilized in endogenous Olig2
isolated from these murine and human progenitor cell types
(see Discussion). Notably, no phosphorylated residues were
detected within a serine/threonine-rich ‘‘box’’ that is a distinctive
feature of all mammalian Olig2 homologs (Lu et al., 2000; Take-
bayashi et al., 2000; Zhou et al., 2000). Instead, high-confidence
phosphorylation sites within endogenous Olig2 were confined to
S10, S13, S14, and T43 within the amino-terminal domain
(Figures 1A, S1, and S2).The Triple Phosphoserine Motif in Olig2 Regulates
Proliferation of Neural Progenitors in Secondary
Neurosphere Assays
Olig2 null progenitor cells can be cultured as neurospheres
in vitro. However, the population doubling time of Olig2-null
progenitors is significantly extended relative to their wild-type
counterparts (43 versus 35 hr, respectively) (Ligon et al.,
2007). The four S/T residues comprising the high-confidence
phosphorylation sites were mutated singly or in combinatorial
fashion to glycine or valine so as to create phospho null Olig2
mutant proteins (Figure 1B). These phospho null variants
were transduced into Olig2-null neural progenitor cells, and
secondary neurosphere assayswere conducted to examine their
roles in proliferation.
As indicated (Figures 1C and 1D), the phosphorylation state
of Olig2 is irrelevant to the total number of neurospheres that
are produced in secondary neurosphere assays. However, the
viable cell count within these neurospheres (and, hence, the
size of the secondary neurospheres) is greatly reduced by phos-
pho null substitutions at S10, S13, and S14 (triple phospho null
[TPN]). Conversely, the substitution of negatively charged
‘‘phosphomimetic’’ amino acids (S -> D or S -> E) at this triple
serine motif (triple phosphomimetic [TPM]) rescues the prolifera-
tive functions of wild-type Olig2 (Figures 1C, 1E, and 1F). The
effects of these phospho null and phosphomimetic amino acid
substitutions on proliferative functions of Olig2 were further
confirmed by pulse-labeling experiments with BrdU (Figure S3).
Western blotting and immunostaining experiments show that
the TPN and TPM substitutions affect neither the expression nor
the subcellular location of Olig2; moreover, the total amount of
ectopicwild-type ormutant Olig2 proteins (produced as transcrip-
tion/translation products of our retroviral expression vectors) is
roughly equivalent to the abundance of endogenous Olig2 protein
in normal neural progenitor cells (Figure S4). Single or double
substitutions at S10, 13, 14 proved to have minimal effect on
neurosphere growth (Figure 1B). Accordingly, all of our further
studies focused on the TPN and TPM variants shown in Figure 1B.
Phosphorylation State of the Olig2 S10/13/14 Motif
Is Developmentally Regulated
Using synthetic phosphopeptides and affinity chromatography,
we prepared a phosphorylation state-specific antibody to the
Olig2 triple serine motif. Specificity of this antibody preparation
was validated by western blot analysis of cells transduced with
wild-type or phospho null variants of Olig2 (Figure 2A) and also
by peptide competition western blots (Figure S6). Using this anti-
body, we examined the phosphorylation state of endogenous
Olig2 in developing mouse embryos. Spinal cord is an anatomi-
cally simple region of the CNS, where the bifunctionality of Olig2
has been clearly documented. As indicated (Figure 2B), the
phosphorylation state of Olig2 undergoes a dramatic decrease
as proliferating Olig2-positive progenitors in the embryo mature
into terminally differentiated, myelinating oligodendrocytes of
the postnatal spinal cord. Developmental regulation of Olig2
phosphorylation can also be observed in vitro, when cycling
progenitor cells are plated in factor-free medium and allowed
to differentiate (Figure 2C). In cell culture it is possible to conduct
pulse-labeling experiments with 32P, and these experimentsNeuron 69, 906–917, March 10, 2011 ª2011 Elsevier Inc. 907
Figure 1. Triple Serine Phosphorylation
Motif in the N Terminus of Olig2 Is Required
for Proliferation of Neural Progenitor Cells
(A) Four phosphorylation sites were identified in
the N terminus of Olig2 by mass spectroscopy.
Three serine sites are in a tight cluster in the N
terminus.
(B) We created a panel of single and multiple
mutants of the phosphorylation sites. Olig2-null
neural progenitor cells were transduced with
each construct of Olig2 via retroviral infection.
Secondary neurosphere assays were performed.
Each construct was compared to Olig2 WT, and
total viable cell population was used as an index
for measuring neurosphere proliferative ability.
(C) Representative neurospheres generated from
cells transduced with control vector (eGFP),
Olig2 WT, Olig2 TPN, and Olig2 TPM reveal size
differences.
(D) Secondary neurosphere numbers were com-
pared. Transduced cells were plated in 6-well
plates at 10 cells/ml (2 ml total volume) in EGF
(20 ng/ml) and bFGF (20 ng/ml) containing
medium. Seven days later, neurospheres from
each well were counted using a dissection micro-
scope. p > 0.05, one-way ANOVA. NS, neuro-
sphere. Error bars, SEM.
(E) Total viable cell population was compared.
One-way ANOVA and post hoc Newman-Keuls
test, ***p < 0.001. Error bars, SD.
(F) Neurosphere sizes were measured with ImageJ
software, and areas were compared. One-way
ANOVA and post hoc Newman-Keuls test, **p <
0.01. NS, neurosphere. Error bars, SEM.
See also Figures S1–S3.
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phorylated Olig2 reflects diminished activity of an Olig2 protein
kinase(s) (Figure 2D). Together these data indicate that the triple
phosphorylation of Olig2 is correlated with proliferation of neural
progenitor cells and is much diminished after differentiation.
Phosphorylation of Olig2 Is Dispensable
for Specification and Terminal Differentiation
of Oligodendrocytes
Targeted disruption of Olig2 results in nearly complete ablation
of the oligodendrocyte lineage in vivo and in vitro (Lu et al.,
2002; Zhou and Anderson, 2002). As shown in Figures 3A and
3B, the ability ofOlig2/ progenitors to develop into O4-positive
cells can be rescued by lentiviral transduction of wild-typeOlig2;
however, unlike the case with secondary neurosphere assays
(Figure 1), the phospho null and phosphomimetic variants of
Olig2 are equipotent to wild-type Olig2 for this developmental
function (Figures 3C and 3D).
To determine whether phosphorylation of Olig2 is required
for terminal differentiation of oligodendrocytes in vivo, we908 Neuron 69, 906–917, March 10, 2011 ª2011 Elsevier Inc.orthotopically transplanted Olig2/ pro-
genitors that had been transduced with
vectors encoding either wild-type or
phospho null Olig2 or GFP (control) intoShiverer (Shi) mice, which are null mutants for myelin basic
protein (MBP). Because Shi mice produce no endogenous
MBP, any detected MBP can be ascribed definitively to myeli-
nating transplanted cells. As shown (Figures 4 and S5), wild-
type and phospho null Olig2-transduced progenitors developed
into oligodendrocytes with characteristic mature morphology
and MBP production in vivo. We conclude that phosphorylation
of Olig2 is dispensable for specification and terminal differentia-
tion of oligodendrocyte lineage cells. These transplantation
results do not rule out the possibility that phosphomimetic
Olig2 might antagonize oligodendrocyte differentiation in vivo.
Phosphorylation State of the Olig2 Triple Serine Motif
Correlates with Oncogenic Potential
Olig2 is expressed in 100% of the human diffuse gliomas regard-
less of grade (Ligon et al., 2004). Beyond merely marking malig-
nant gliomas, Olig2 expression is required for intracranial tumor
formation in a genetically relevant model of malignant glioma
(Ligon et al., 2007). In this model, neural progenitor cells from
p16Ink4a/p19Arf null mice are transduced with the mutated,
Figure 2. Triple Serine Phosphorylation State in Olig2
Is Regulated Developmentally
(A) Olig2 phospho-specific antibody detects phosphorylation
in wild-type Olig2, but not in triple phosphomutant or any
single serine mutant. Olig2-null neural progenitor cells bearing
different Olig2 phosphorylation mutants were lysed, and the
state of phosphorylation at S10, S13, and S14 was analyzed
by western blot using phospho-specific Olig2 antibody. The
blot was then stripped and reprobed with polyclonal antibody
to total Olig2.
(B) Olig2 triple serine phosphorylation state decreases with
increasing developmental stage of spinal cord. Whole spinal
cords were dissected from E15 and E17 embryos and P23–
25 CD1 mice. Protein lysates (40 mg) in RIPA buffer were
loaded for immunoblotting, probed for phospho-Olig2 anti-
body, and then reprobed with a monoclonal Olig2 antibody.
(C) Triple serine phosphorylation decreased as neurospheres
are allowed to become adherent and differentiate in growth
factor-free medium. Olig2 WT neurospheres were rinsed
once with ice-cold PBS medium and then plated in B27 con-
tainingmedium in poly-l-ornithine coated plates. Sixteen hours
later, cell lysates were collected and compared to undifferentiated neurosphere lysate (T0) by western blot.
(D) 32P-pulse labeling of neurospheres in the presence (T0) or absence of EGF and bFGF. No 32P incorporation in Olig2 is observed after overnight differentiation
(16 hr). Autoradiogram (phosphorylated Olig2) and western blots (total Olig2 and vinculin loading control).
See also Figure S4.
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factor receptor (Bachoo et al., 2002). These genetically engi-
neered ‘‘tumor neurospheres’’ recapitulate two stereotypical
genetic lesions that drive a high percentage of human gliomas
(Kleihues and Cavenee, 2007; Cancer Genome Atlas Research
Network, 2008).
As indicated in Figure 5, the malignant potential of Olig2-null
tumor neurospheres is much impaired. Even when a high
number (105) of Olig-null tumor neurospheres are inoculated
into the brain, tumor penetrance is low, and latency is long.
Tumor formation is rescued by transduction of wild-type Olig2
and the two Olig2 variants; however endpoint dilution experi-
ments reveal a phosphorylation-dependent differential in the
malignant phenotype. Relative to wild-type Olig2, both the lag
time to tumor development and the minimum inoculum of tumor
cells required for tumor formation are increased with the phos-
pho null form of Olig2. Conversely, the phosphomimetic form
of Olig2 is more tumorigenic than either wild-type or phospho
null Olig2.
What about human gliomas? Although technically impractical
to assess the function of Olig2 phosphorylation in the human
tumors, we did use our phospho-specific antibody to interrogate
Olig2 phosphorylation state within six human glioma neuro-
sphere cultures. As reference points, we used Olig2 from cycling
mouse neurosphere cultures and from terminally differentiated
oligodendrocytes in the mouse corpus callosum. As indicated
(Figure 6), the phosphorylation state of Olig2 was analogous
to that of cycling murine progenitor cells rather than corpus
callosum for five out of the six lines tested. Interestingly, the
exception (one of six lines tested) was a p53 null tumor cell
line. In other studies we have found an intrinsic oppositional rela-
tionship between Olig2 and p53 (Mehta et al., 2011) such that
Olig2 function (and presumably phosphorylation) is irrelevant in
a p53 null context. Together, these findings indicate that Olig2
phosphorylation at the triple serine motif is present in humanglioma and regulates tumor growth in a genetically relevant
mouse orthotopic model.
Olig2 Phosphorylation State Regulates p53 Function
What is the molecular mechanism that links Olig2 phosphoryla-
tion to neurosphere growth and formation of malignant
gliomas? A companion paper by Mehta et al. (2011) describes
an intrinsic oppositional relationship between Olig2 and p53.
Put briefly, Mehta et al. (2011) show that expression of Olig2
suppresses the posttranslational acetylation of p53, which is
known to be required for optimum transcriptional functions
(Barlev et al., 2001; Dornan et al., 2003). Concurrent with hypo-
acetylation, the interactions of p53 with promoter/enhancer
elements of its stereotypical target genes (e.g., p21,$Bax,
Mdm2) are much attenuated in wild-type neural progenitors
relative to their Olig2-null counterparts. Accordingly, p53-medi-
ated biological responses to genotoxic damage are suppressed
by Olig2.
Experiments summarized in Figure 7 show that this opposi-
tional relationship between Olig2 and p53 is regulated by the
phosphorylation state of the triple serine motif. Wild-type and
also phosphomimetic Olig2 suppress the radiation-induced
increase in both total p53 (Figure 7A) and acetylated p53 (Fig-
ure 7B). Likewise, wild-type and phosphomimetic Olig2 sup-
press radiation-induced expression of the canonical p53 target
gene p21 (Figure 7C, inset). Concurrent with suppression of
p21 expression, wild-type and phosphomimetic Olig2 promote
the survival of irradiated neural progenitors, as noted by Mehta
et al. (2011) (Figure 7C). In marked contrast, phospho null
Olig2 is deficient in all of these functions.
In previous studies we have shown that basal levels of p21
expression seen in cycling neural progenitor cells are also sup-
pressed by Olig2 (Ligon et al., 2007). As shown in Figure 8A
(inset), wild-type and phosphomimetic Olig2 suppress basal
levels of p21 protein, whereas phospho null Olig2 shows littleNeuron 69, 906–917, March 10, 2011 ª2011 Elsevier Inc. 909
Figure 3. Triple Serine Phosphorylation
in Olig2 Is Negligible in Specification of
Oligodendrocytes
(A) Olig2 is required for the generation of O4-posi-
tive oligodendrocytes. Neural progenitor cells
were isolated from the E12 LGE region, plated at
clonal density, and cultured in bFGF-containing
medium. Cells were stained with antibody to total
Olig2 or O4 at day 7. Scale bar, 100 mm.
(B) The frequency of O4-positive cells was
compared among Olig2+/+, Olig2+/, and Olig2/
embryos. ***p < 0.001, ANOVA and post hoc New-
man-Keuls test; three embryos for each genotype.
Error bars, SEM. ND, none detected.
(C) Triple serine phospho null, phosphomimetic,
and Olig2 WT reveal similar abilities in rescuing
O4-positive cells. Lentivirus bearing wild-type
(WT), TPN, or TPM was used to infect Olig2-null
E12 LGE progenitor cells at an MOI of 1:1. Cells
were analyzed at day 9–10. Scale bar, 100 mm.
(D) The ratios of O4-positive cells among the
infected cells (identified with either GFP or
Olig2 staining) were compared. **p < 0.01,
ANOVA and post hoc Newman-Keuls test (n = 3
independent experiments). ND, none detected.
Error bars, SEM.
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protein is exerted largely at transcriptional level, as indicated
by diminished expression of p21 mRNA (Figure 8A). Expression
of a p21 luciferase reporter gene is likewise controlled by Olig2
in a phosphorylation state-dependent manner (Figure S8). This
suppression of basal state p21 mRNA reflects, at least in part,
phospho Olig2-regulated changes in the amount of p53 that is
associated with promoter/enhancer elements of the p21 gene
(Figure 8B). The differential loading of p53 onto p21 promoter
enhancer element is nuanced but statistically significant and
also in good accord with the basal state levels of acetylated
p53 seen in Figure 7B.
On a final note, the phosphorylation state-dependent effects
of Olig2 on neurosphere proliferation noted in Figure 1 are
completely dependent on p53 status. As seen in Figures 8C
and 8D, the phosphorylation state of Olig2 is irrelevant in p53910 Neuron 69, 906–917, March 10, 2011 ª2011 Elsevier Inc.null neurospheres—at least with respect
to cell proliferation. Collectively, these
data show that p53 is a significant target
of phosphorylated Olig2 in neural
progenitors.
DISCUSSION
The bHLH transcription factor Olig2 is ex-
pressed in multipotent progenitors of the
embryonic brain (Petryniak et al., 2007)
and in the postnatal brain within cell types
that span a biological continuum from
rapidly cycling neural progenitors (e.g.,
type C cells, NG2 cells) to terminally
differentiated, myelinating oligodendro-cytes (Jackson et al., 2006; Ligon et al., 2006; Lu et al., 2000;
Menn et al., 2006; Takebayashi et al., 2000; Zhou et al., 2000).
How are the transcriptional functions of Olig2 modulated to
suit these divergent biological contexts? We show here that
a developmentally regulated phosphoserine motif in the amino
terminus is essential for Olig2 proliferative function in both
normal and malignant neural progenitors. On a mechanistic level
the promitotic activity of this triple serine motif appears to reflect
a suppression of p53 functions. In contrast to proliferative
functions, specification and terminal differentiation of oligoden-
drocytes are completely independent of Olig2 triple serine phos-
phorylation state. In the fullness of time, the ability to uncouple
proliferative and developmental functions of Olig2 may thus
have practical applications in glioma medicine. In the interim
the observations summarized here raise several interesting and
unresolved scientific questions.
Figure 4. Triple Serine Phosphorylation in
Olig2 Is Not Required for Maturation of
Oligodendrocytes
Olig2-null neurospheres obtained from E14.5
Olig2cre/cre (null); Rosa26-STOP-flox-eYFP
embryos were transduced with retrovirus contain-
ing expression constructs of eGFP, Olig2-V5 (WT),
and Olig2-phospho null-V5 (TPN), respectively.
Neurospheres were then transplanted into lateral
ventricle of newborn Shi mice that lack MBP
expression. The transplanted brains were
sectioned and examined for MBP (red), eGFP
(green in A), and V5 (green in B and C) expression.
(A) Of the eGFP-positive Olig2-null cells, 0%
expresses MBP, whereas 13.8% of the Olig2-V5
expressing cells and 16.4% of the Olig2-phospho
null-V5 expressing cells express MBPs (B and C).
See also Figure S5.
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Phosphorylation Sites on Olig2?
Computer algorithms reveal a number of potential phosphoryla-
tion sites on Olig2 (Figure S1A). To determine which, if any, of
these potential sites are actually utilized in neural stem cells,
we developed a simple two-step protocol to purify microgram
quantities of endogenous Olig2 from human glioma and murine
neurosphere cultures. For comparative purposes we also puri-
fied ectopic Olig2 from COS cells transfected with a human
Olig2 expression vector. Only a subset of the potential Olig2
phosphorylation sites cataloged is actually detected in these
cells. Four amino acid residues, S10, S13, S14, and T43, scored
as ‘‘high confidence’’ phosphorylation sites in all three of the cell
types we examined.
It is possible that a small percentage of the Olig2 protein,
below the detection limits of our mass spectroscopic analysis,
is phosphorylated at other positions in biologically relevant cell
contexts. This caveat must be considered in particular for poten-
tial phosphorylation motifs in the carboxyl terminal domain of
Olig2, where proteolytic digestion sites are rather sparse. That
said, we actually did detect a high-confidence phosphorylation
site in the carboxyl terminus (S263) in ectopic Olig2 purified
from transfected COS cells (data not shown). Another phospho-
serine residue was found at S81 in the ‘‘S/T box’’ of COS cell-
purified Olig2 (see below). However, we find no evidence that
S81 or S263 is phosphorylated on the endogenous Olig2 protein
expressed in neural cell types. As previously reported, a consid-
erable fraction of ectopic Olig2 in transfected COS cells is mislo-
calized to the cytosol (Sun et al., 2003). The level of ectopic Olig2
generated by COS cell expression vectors is so high that we did
not need to use isolated nuclei as a source of startingmaterial for
our protein preparations and, instead, extracted both nuclear
and cytosolic Olig2. For these reasons we are inclined to regardNeuron 69, 906–91the S81 and S263 phosphorylation
events as cytosol-specific artifacts of
the COS cell system.
Setoguchi and Kondo (2004) have
suggested (on the basis of in vitro phos-
phorylation studies) that AKT-mediatedphosphorylation of S30 causes Olig2 to relocalize from the
nucleus to thecytosol,where it is subsequently degraded toallow
formation of astrocytes from neural progenitor cells. We did not
detect any evidence of S30 phosphorylation in nuclear extracts
of the neural cell types we studied. However, S30 was detected
as a low-confidence phosphorylation site in COS cell extracts.
The detection of low levels of phospho S30 in ourmass spectros-
copy analysis of COS cell Olig2 may have been enabled by the
large amounts of cytosolic Olig2 in the COS cell preparations
and would thus be consistent with a degradative role of S30, as
suggested by Setoguchi and Kondo (2004) (but see below).
Phylogenetic Conservation of the Triple Serine Motif
in Vertebrates
Critical primary and secondary structural features of proteins are
conserved through evolution. Myelinating oligodendrocytes are
detected in all vertebrates above the jawless fish. As indicated
in Figure S7, the triple serine motif and its flanking amino acid
residues are well conserved in Olig2 from human down through
zebrafish. In fact, the triple serine motif of Olig2 is nearly as well
conserved as the DNA-targeting bHLH motif. The other high-
confidence phosphorylation site at T43 is likewise well
conserved. By contrast the S30 region of Olig2 (Setoguchi and
Kondo, 2004) does not seem to be well conserved.
Murine Olig2 and its close structural homolog Olig1 contain
a serine/threonine-rich ‘‘box’’ toward the amino-terminal side
of the DNA-targeting bHLH domain (Lu et al., 2000; Takebayashi
et al., 2000; Zhou et al., 2000). In murine Olig2 this S/T box is an
especially distinctive feature, containing 11 contiguous S or T
residues beginning at S77 and ending at S88 (Figure S1). We
were somewhat surprised that our mass spectroscopy analysis
of endogenous Olig2 detected no evidence of phosphoserine
or phosphothreonine residues within this S/T box.7, March 10, 2011 ª2011 Elsevier Inc. 911
Figure 5. Phosphorylation State of the Olig2 Triple Serine Motif Correlates with Oncogenic Potential
(A) Ink4a/Arf/ Olig2/ EGFRVIII murine neural progenitor cell line EB5 was stably transduced with eGFP, Olig2 WT, Olig2 triple null (TPN), or Olig2
phosphomimetic (TPM) via retroviral infection. Tumorigenic potential of each line was compared using a limiting dilution assay. For each construct, 105, 104,
103, or 102 dissociated neural progenitor cells were injected intracranially, and the survival of each mouse was recorded (for the eGFP control group, 105
were injected). Expression levels of each Olig2 construct in the EB5 line were examined by western blot for phosphorylated Olig2 and total Olig2 (right panel).
Vinculin expression was used as a loading control.
(B) Same as (A) but with another independently derived Ink4a/Arf/ Olig2/ EGFRVIII murine neural progenitor cell line, EB7.
Neuron
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rapidly down through phylogeny (in contrast to the triple serine
motif). Beginning with chicken and moving downward to
XenopusOlig2, an increasing number of the serines are replaced
by alanine residues. In space-filling models, alanine and serine
residues are roughly equivalent, suggesting that size rather
than phosphorylation potential is the critical structural feature
of the S/T box. However, at the level of zebrafish, even this
small-volume ‘‘S/T’’ box has largely disappeared. In addition it
should be noted that no version of vertebrate Olig3 displays an
S/T box, even though mammalian Olig3 proteins are virtually
identical to mammalian Olig2 within the DNA-targeting bHLH
motif (Takebayashi et al., 2000).
Developmental Regulation of Replication Competence
by Olig2 in the CNS
In this study we have focused on evolving functions of Olig2 in
multipotent progenitors of the developing forebrain and in mye-
linating oligodendrocytes of the postnatal brain. However, in the
developing spinal cord, Olig2 is expressed initially in the pMN
domain, where it functions at early times to sustain the replica-
tion competent state of those pMN progenitors that give rise to
oligodendrocytes (Lee et al., 2005). Olig2 function is also
required for neural patterning and specification of motor neurons
and oligodendrocyte progenitors (Lu et al., 2002; Novitch et al.,
2001; Park et al., 2002; Takebayashi et al., 2002; Zhou and
Anderson, 2002). So, might phosphorylation of the Olig2 triple912 Neuron 69, 906–917, March 10, 2011 ª2011 Elsevier Inc.serine motif also be responsible for the developmental switch
from pMN progenitor proliferation to cell fate specification in
the embryo? The answer to this question may be complex.
Indeed, Olig2-null animals show no obvious proliferation pheno-
type in spinal cord or brain (Lu et al., 2002; Novitch et al., 2001;
Park et al., 2002; Takebayashi et al., 2002; Zhou and Anderson,
2002). This lack of a proliferation phenotype is most probably
accounted for by the dramatic changes in neural patterning in
Olig2-null embryos, whereby the pMN domain is respecified to
p2 fate, coupled with the fact that the p2 domain contains
independent mechanisms for cell cycle regulation capable of
supporting similar levels of progenitor proliferation. Therefore,
further work using knockin mutants of phospho null Olig2 is
required to investigate possible roles for Olig2 in embryonic
progenitor proliferation, and such studies are in progress.
Regulation of p53 Functions by the Triple Serine Motif
In a companion paper, Mehta et al. (2011) show that Olig2
suppresses radiation-induced functions of p53 in both normal
and malignant neural progenitors. We show here that this
intrinsic oppositional relationship between Olig2 and p53 is
regulated by the Olig2 triple serine motif. Wild-type and also
phosphomimetic Olig2 suppress the classic radiation-induced
accumulation of p53 protein, whereas phospho null Olig2 is
permissive for this response (Figure 7A). We have generated
mRNA expression profiles on Olig2 wild-type, Olig2-null, Olig2
phospho null, and Olig2 phosphomimetic neurospheres. These
Figure 6. Phosphorylation of Olig2 in Human Glioma Cell Lines
Several human glioma cell lines were examined for their levels of Olig2 phos-
phorylation using the phosphorylation state-specific antibody by western blot.
WTmn, wild-type mouse neurospheres; MCC, mouse corpus callosum; BT,
brain tumor cell line. Western blots were quantitated using a Typhoon Imaging
System, and values in the graph are representative of three independent
repeats. BT74 denotes the only human tumor cell line in this study that harbors
a mutant form of p53. See also Figure S6.
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mRNA levels (data not shown). Rather, it appears that wild-
type and phosphomimetic Olig2 suppress radiation-induced
posttranslational acetylation events that enhance both the
stability (Li et al., 2002) and the transcriptional functions (Barlev
et al., 2001) of p53 (Figure 7B).
In addition to their guardian functions in response to genotoxic
damage, p53 and p21 are known to regulate the proliferation of
normal neural progenitors (Kippin et al., 2005; Meletis et al.,
2006). As shown in Figure 8, wild-type and phosphomimetic
Olig2 suppress basal expression of p21 protein and mRNA in
cycling cells. These effects are reflected, at least in part, by
diminished levels of p53 protein associated with promoter/
enhancer elements of the p21 gene. However, the pronounced
impact of Olig2 phosphorylation on expression of p21 protein
and mRNA (Figure 8A) stands somewhat in contrast to the
more nuanced differences in total p53 bound to p21 promoter/
enhancer elements (Figure 8B). Expression of p21 protein and
mRNA is likely to reflect the cumulative impact of reduced p53
recruitment to the p21 promoter, reduced transcriptional func-
tion of hypoacetylated p53 at the promoter (Barlev et al.,
2001), and possible posttranscriptional effects on stability of
the p21 protein (Coleman et al., 2003; Gong et al., 2003). In addi-
tion we have shown in previous studies that Olig2 can interact
directly with the promoter/enhancer elements of p21 (Ligon
et al., 2007). Because Olig2 has been characterized as a tran-
scription repressor (Novitch et al., 2001; Zhou et al., 2001), it is
possible that the attenuation of p53 transcriptional functions is
further augmented by direct Olig2-mediated suppression of
p21 expression (however, see below). Notwithstanding the
complexity of p21 regulatory mechanisms, the experimentsummarized in Figures 8C and 8D shows clearly that p53 is
a prime target of the Olig2 proliferative phenotype.
Regulation of Olig2 Functions by the Triple Serine Motif
How does phosphorylation of the triple serine motif affect
transcriptional functions of Olig2? Members of the bHLH tran-
scription factor family function as homodimers or as hetero-
dimers with E12/E47 proteins to bind to canonical E box
elements in the promoter/enhancer regions of their target genes
(Ross et al., 2003). The bHLH motif is almost exclusively respon-
sible for both heterodimerization and DNA targeting to the E box.
It seems unlikely that phosphorylation events in the amino
terminus would have any direct effect on these functions of
Olig2, and preliminary chromatin immunoprecipitation (ChIP)
studies failed to show changes in Olig2:p21 targeting that could
account for the effects on basal p21 expression of p21 seen in
Figure 8A.
The fact that all three serine residues at positions 10, 13, and
14 must be mutated to achieve a strong loss-of-function or
gain-of-function phenotype suggests that the proliferative func-
tion associated with the Olig2 phosphorylation state involves
a significant conformational change in the amino terminus of
Olig2. This conformational change could affect the interaction
of Olig2 with DNA or important coregulator proteins and, thus,
affect the transcriptional activity of Olig2 upon target genes
that affect p53 function. One final possibility that cannot be ruled
out by the data is that the p53 antagonist function of Olig2 is
independent of its function as a bHLH transcription factor. It is
possible, for example, that phosphorylated Olig2 competes
directly with p53 for binding to proteins that promote p53 acety-
lation or prevent its deacetylation. In fact preliminary observa-
tions of Mehta et al. (2011) suggest such a mechanism.
Phosphorylation State of Olig2 and Malignant Potential
In a murine model of primary glioma, the tumor penetrance is
quite low, and latency is prolonged in the absence of Olig2
expression (Figure 5; Ligon et al. [2007]). A forced phosphomi-
metic Olig2 state actually enhances intracranial tumor formation
relative to wild-type Olig2. We speculate that the enhanced
performance of the phosphomimetic Olig2 relative to the wild-
type protein in vivo reflects the fact that some of the implanted
cells expressing wild-type Olig2 undergo differentiation with
attendant dephosphorylation, whereas the mutant form of
Olig2 is locked into a phosphomimetic configuration.
An unexplained feature of the limiting dilution assays for tumor
growth (Figure 5) is that the phospho null form of Olig2, though
clearly inferior to wild-type and phosphomimetic Olig2, is able
to support tumor growth when large numbers of cells are trans-
planted. Based on the p21 suppression results, particularly the
inability of the TPN mutant form of Olig2 to suppress p21, one
might predict that phospho null Olig2 would be completely non-
tumorigenic. How does one account for the residual tumorigenic
potential of phospho null Olig2? In a companion paper to this
one, Mehta et al. (2011) show that the major role of Olig2 in
promoting intracranial tumor formation is to suppress the func-
tions of p53. However, these workers also noted a somewhat
nuanced p53-independent function(s) of Olig2 in tumor forma-
tion. It is possible that the p53-independent functions of Olig2Neuron 69, 906–917, March 10, 2011 ª2011 Elsevier Inc. 913
Figure 7. Wild-Type and Phosphomimetic Olig2 Suppress Radiation-Induced p53 Responses
(A) Phosphorylation state of Olig2 affects DNA damage-induced accumulation of p53 protein.Olig2/mouse neural progenitor cells were stably transduced with
a vector control (eGFP) or with Olig2 WT, Olig2 TPN, or TPM as indicated. Cells were either untreated or treated with 2 Gy of IR, and lysates were obtained in
presence of HDAC inhibitor, size fractionated, and immunoblotted with antibodies recognizing p53 or b-actin. The experiments were repeated a total of five times.
The resulting immunoblots (inset) were normalized for b-actin and quantified (bar graphs). As indicated, wild-type and also phosphomimetic Olig2 suppress
radiation-induced changes in total p53, but phospho null Olig2 is without effect (*p < 0.01, two-way ANOVA and Bonferroni post hoc test). In nonirradiated cells
(white bars), the differences in total p53 between the four experimental groups did not approach the level of statistical significance. Error bars, SEM.
(B) Phosphorylation state of Olig2 affects DNA damage-induced acetylation of p53 protein. Same as (A), except that cell lysates immunoblotted with antibodies
recognize acetylated p53 (Lys379) or b-actin. Again, wild-type and phosphomimetic Olig2 suppress radiation-induced changes in acetylated p53, whereas
phospho null Olig2 is without effect (*p < 0.05). Relative to vector controls, wild-type and phosphomimetic Olig2 create a small, but significant, suppression
of acetylated p53 in nonirradiated cells (white bars). *p < 0.05, **p < 0.01, ***p < 0.001, two-way ANOVA and Bonferroni post hoc test. Error bars, SEM.
(C) Inset shows that phosphorylation state of Olig2 dictates p21 expression level and cell survival following gamma irradiation. Cells were irradiated with 2 Gy IR.
Endogenous p21 expression levels were compared by western blot with b-actin as a loading control. Bar graph shows relative cell growth after 2 Gy irradiation.
Total viable cells are defined as the percentage of viable cells 4–5 days after treatment compared to nontreatment groups. Data presented are from three
independent experiments. Error bar, SD. One-way ANOVA, p < 0.001. Post hoc Newman-Keuls test, **p < 0.01 and ***p < 0.001.
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pendent of phosphorylation state.The Triple Serine Motif as a Drug Target for Malignant
Glioma
Chemical tool compounds and hairpin RNA expression vectors,
used in combination with our phospho-specific antibody (Fig-
ure 2), should ultimately lead to identification of protein kinases
that regulate the phosphorylation state of S10, S13, and S14.
Phosphorylation modeling programs such as Scansite, GPS,
and PredPhospho as well as direct evaluation yield some over-
lapping predictions for kinase candidates but also different
predictions for each of the three serine residues. Among the
best-represented predictions are CDK5, ERK kinases (ERK1,
2/MAPK), GSK3, and casein kinases (CK1/2). In neurosphere
proliferation assays we were unable to narrow the phenotype
of TPN Olig2 down to a single serine site, which argues against
the existence of a priming site. However, an intramolecular
cascade may be operative if GSK3 acts at Ser10, as predicted
by the computer algorithms. GSK3 would require prephosphor-
ylation of Ser14 to create the motif S/TXXXpS/pT. Likewise,
phosphorylation of Ser13 is prerequisite for CK2 to phosphory-
late S10 (PhosphoMotif, http://www.hprd.org).
Olig2 is a lineage-restricted regulatory transcription factor
whose expression is confined to the CNS. The expression
pattern of Olig2 in human tissue microarrays (Ligon et al.,
2004), combined with mouse modeling studies of human glioma914 Neuron 69, 906–917, March 10, 2011 ª2011 Elsevier Inc.(Ligon et al., 2007), has suggested to us that a small molecule
inhibitor of Olig2 might serve as a targeted therapeutic for
a wide range of pediatric and adult gliomas. However, an anti-
tumor therapy that generally targets all Olig2 activity in the brain
(e.g., by shRNA) would likely have detrimental, off-target effects
in nontumor cells, such as oligodendrocytes potentially limiting
tolerance/utility. Moreover, transcription factors are generally
considered unattractive targets for drug development because
their interactions with DNA and with coregulator proteins involve
large and complex surface area contacts.
In contrast to transcription factors, protein kinases lend them-
selves readily to the development of potent and specific small
molecule inhibitors. Our studies indicate that Olig2 functions crit-
ical for glioma growth (Figure 5) and radiation resistance (Fig-
ure 7), but not development (Figures 3 and 4), are distinguished
by the triple serine phosphorylation. The ability to uncouple these
functions one from the other suggests an avenue to specifically
target Olig2-dependent tumors within the brain while sparing
normal white matter. In the fullness of time, small molecule inhib-
itors of Olig2 protein kinases could have practical overtones for
patients with glioma and provide a more specific means of
therapy with minimized off-target effects in oligodendrocytes.
EXPERIMENTAL PROCEDURES
Animal Procedures, Tissue Dissociation, and Cell Culture
Animal husbandry was performed according to DFCI and UCSF guidelines
under IACUC-approved protocols for all experiments reported. The strains
Figure 8. An Oppositional Relationship
between Olig2 and p53 in Cycling Neural
Progenitors
(A) Endogenous p21 protein (inset) and mRNA (bar
graphs) are suppressed by wild-type and phos-
phomimetic Olig2 in cycling neural progenitors.
Olig2/mouse neural progenitor cells were stably
transduced with vector control (eGFP), WT, TPN,
or TPM. Endogenous protein levels were com-
pared by western blotting with p21 antibody and
b-actin as control. RNA was extracted from cells
as described above, and p21 mRNA levels were
quantified using premade p21 TaqMan gene
expression assay. Error bars, SD.
(B) Expression of p21 in cycling neural progenitors
correlates with p53 loading on promoter/enhancer
elements of the p21 promoter. Lysates of Olig2/
mouse neural progenitor cells stably transduced
with vector control (eGFP), WT, TPN, or TPM
were processed for ChIP with p53 antibody.
Primers spanning the distal E box in the p21
promoter/enhancer region were used for qRT-
PCR analysis. Bar graph shows p21 promoter
binding normalized for nontarget site enrichment.
Note that the differences in p53 loading, between
the four groups, though nuanced, are statistically
significant (**p < 0.01, ***p < 0.001) and in good
accord with differences noted in acetylated
p53 seen in cycling cells (Figure 7B). Error bars,
SEM.
(C) Phosphorylation state of Olig2 is irrelevant in
p53 null neurospheres. Olig2cre/cre mice were in-
tercrossed to p53fl/fl mice to obtain neural
progenitors that were Olig2:p53 double null. These
progenitors were transduced with eGFP, wild-type
Olig2, or the TPN mutant of Olig2 as indicated.
Secondary neurosphere assays were performed
on these cells and on matched p53 +/+ controls
as per Figure 1.
(D) Quantitation of neurosphere (NS) counts and
sizes from (C). Neurosphere size was measured
using ImageJ. Error bars, SD.
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Olig2 Phosphorylation in Neural Progenitorsused have been described previously (Lu et al., 2002; Schuller et al., 2008). Shi
mice were obtained from Jackson Laboratory. Neural progenitor cells were
isolated from lateral ganglionic eminence (LGE) of E12–E14 embryos from
time-pregnant mice using techniques previously described (Qian et al., 1998).
Olig2 Protein Purification and Phosphorylation Analysis
Endogenous Olig2 protein was purified from in vitro-cultured murine LGE
neurospheres (5 g total pellet weight; derived from E14 embryos of CD1
time-pregnant mice; Charles River) and human glioma line BT37 mouse xeno-
grafts (15 g total tissue weight) by generating nuclear extracts that were then
subjected to Olig2 antibody affinity column chromatography. The affinity
column was generated using Olig2 antibody according to the instructions of
AminoLink Plus Immobilization Kit (Pierce). Purified Olig2 protein was sub-
jected to SDS-PAGE followed by Coomassie blue staining. Bands corre-
sponding to Olig2 protein were excised and sent to the Taplin Biological
Mass Spectrometry Facility (Harvard Medical School) for protein identification
and Olig2 phosphorylation analysis using LC/MS/MS. Details can be found in
Supplemental Experimental Procedures.Secondary Neurosphere Assay
Olig2-null neural progenitor cell lines were derived from the LGE of individual
E14 Olig2-null embryos and maintained as neurosphere cultures. After three
passages, neurospheres were dissociated into single cells and then trans-
duced with retroviruses containing various mutants of Olig2 at an MOI of
0.5:1 under neurosphere culture conditions. Transduced cells were selected
with blasticidin for 7 days. Primary transduced neurospheres were dissociated
into single cells and replated at 10 cells/ml in 6-well plates for secondary neuro-
sphere formation assays. For each construct, tertiary neurosphere assays
were performed to confirm the results seen in secondary neurosphere assay.
The expression of each construct was confirmed with western blot and
immunocytochemistry. For total cell population analyses, total neurospheres
from each 6-well were collected andmechanically dissociated into single cells.
Total viable cells were counted with hemocytometer using 0.2% trypan blue
exclusion. Total neurosphere numbers were counted under a dissection
microscope. The images of individual neurospheres were taken using a
43 objective, and ImageJ software was used for measuring neurosphere
size (area).Neuron 69, 906–917, March 10, 2011 ª2011 Elsevier Inc. 915
Neuron
Olig2 Phosphorylation in Neural ProgenitorsMyelination Assay in Shi Mice
Neurospheres isolated from E14.5 Olig2-null embryos were stably transduced
with retrovirus expressing eGFP, Olig2-wt-V5, or Olig2-TPN-V5. Transduced
neurospheres were dissociated into single-cell suspension, and 50,000–
150,000 cells were injected into the lateral ventricles of homozygous newborn
Shi mice (Jackson Laboratory). Recipient mice were sacrificed at postnatal
day 30, perfused, and postfixed overnight with 4% paraformaldehyde. Brains
were dissected, sectioned at 50 mm, and stained for chicken anti-GFP (Aves
Labs), rat anti-MBP (Chemicon), and rabbit anti-V5 (Invitrogen).
32P Labeling of Cells
Cells were labeled for 2 hr in phosphate-free media supplemented with
300 mCi/ml 32P orthophosphate. Cells were washed in cold PBS and protein
extracts generated using RIPA buffer. Olig2 was immune precipitated using
a pan-olig2 antibody (Arnett et al., 2004) and resolved using SDS-PAGE. Quan-
titation of the signal was performed using a Typhoon Trio (GE Healthcare).
Generation and Characterization of Phospho-Specific Antibodies
Phosphorylation state-specific antibodies were generated and purified as
described previously (Alberta and Segal, 2001) using a peptide containing
the triple phosphorylation motif (LVSpSRPpSpSPEPDDLC) conjugated to
KLH using the Imject Conjugation kit (Pierce) as antigen in rabbits by Covance
(Denver, PA, USA).
Limiting Dilution Tumorigenesis Assay
Two Ink4A/ARF/ Olig2/ EGFRVIII neurosphere lines (EB5 and EB7)
were generated as described (Ligon et al., 2007), and then stably transduced
with eGFP, Olig2 WT, and Olig2 mutants of interest via retroviral infection and
five passages of neurosphere expansion. For each Olig2 construct, serial
dilutions of cells at 1 3 105, 1 3 104, 1 3 103, and 1 3 102 were injected
into the right striatum of Icr-SCID mice (Taconic Farms, Inc.) at the coordi-
nates: A, 0.5 mm; L, 1.50 mm; and D, 2.65 mm, relative to the bregma.
Animals were sacrificed at the onset of neurological/clinical symptoms.
ChIP
Olig2/mouse neural progenitor cells were stably transduced with retrovirus
expressing eGFP, Olig2 WT, Olig2 TPN, or Olig2 TPM as described above.
Cells were plated at a density of 10 cells/ml and cultured on laminin-coated
6-well plates (Pollard et al., 2009). Cells were crosslinked with 1% formalde-
hyde for 10 min at RT. Reaction was quenched with 125 mM glycine for
5 min at RT. The cells were washed twice, and harvested in ice-cold PBS,
resuspended in 300 ml SDS lysis buffer, and sonicated with three pulses of
10 s each. Chromatin was diluted in ChIP dilution buffer and precleared for
1 hr at 4C in the presence of 25 ml Dynal magnetic beads (Invitrogen). For
immunoprecipitation, 50 ml beads were incubated with p53 antibody (Santa
Cruz) for 5 hr at 4C. Precleared chromatin and antibody-bound beads were
incubated overnight on a rotor at 4C. Beads were then washed six times in
RIPA wash buffer and twice in TE. Beads were resuspended in 100 ml buffer
(200 mM NaCL, 1% SDS, and 0.1 M NaHCO3) and reverse crosslinked
overnight at 65C. Immunoprecipitated DNA was cleaned with PCR cleanup
kit (QIAGEN) and eluted in ddH2O.
Quantitative PCR
Chromatin-immunoprecipitated DNA was analyzed with quantitative PCR
in real-time PCR system (Applied Biosystems), using SYBR greenmix. Primers
used for qPCR are as described in detail elsewhere (Mehta et al., 2011).
Presented data are delta CT values normalized for WT promoter occupancy.
Radiation Sensitivity Assay
Olig2/ mouse neural progenitor cells stably transduced with eGFP, Olig2
WT, Olig2 TPN, or Olig2 TPM were cultured under adherent culture condition
as described above. Cells were allowed to recover for 3 hr and then treated
with 2 Gy irradiation. Control groups remained untreated. At 4–5 days after
treatment, viable cells were counted by trypan blue exclusion. Data are pre-
sented as percentage of total viable cell number after treatment relative to
untreated controls.916 Neuron 69, 906–917, March 10, 2011 ª2011 Elsevier Inc.Immunoblotting
Total Olig2 immunoblotting was performed according to standard protocols
using either a rabbit polyclonal anti-Olig2 antibody (1:100,000) or amonoclonal
mouse anti-Olig2 antibody (1:2,000) (Arnett et al., 2004).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and eight figures and can be found with this article online at doi:10.1016/
j.neuron.2011.02.005.
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